Pharmacotherapy for depression and treatment-resistant depression:
Gespeichert in:
| Hauptverfasser: | , |
|---|---|
| Format: | Buch |
| Sprache: | English |
| Veröffentlicht: |
Hackensack, NJ [u.a.]
World Scientific
2010
|
| Schlagworte: | |
| Online-Zugang: | Klappentext Inhaltsverzeichnis |
| Beschreibung: | Includes bibliographical references and index pt. 1. First-line pharmacotherapy strategies -- pt. 2. Next-step treatment strategies -- pt. 3. Maintaining treatment gains -- pt. 4. Future directions in treatment development |
| Beschreibung: | xxv, 699 p. graph. Darst. |
| ISBN: | 9789814287586 981428758X 9789814287593 |
Internformat
MARC
| LEADER | 00000nam a2200000zc 4500 | ||
|---|---|---|---|
| 001 | BV040255451 | ||
| 003 | DE-604 | ||
| 005 | 20120725 | ||
| 007 | t | ||
| 008 | 120616s2010 d||| |||| 00||| eng d | ||
| 020 | |a 9789814287586 |9 978-981-4287-58-6 | ||
| 020 | |a 981428758X |9 981-4287-58-X | ||
| 020 | |a 9789814287593 |c ebook |9 978-981-4287-59-3 | ||
| 035 | |a (OCoLC)802350605 | ||
| 035 | |a (DE-599)BVBBV040255451 | ||
| 040 | |a DE-604 |b ger |e aacr | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-355 | ||
| 084 | |a XI 5800 |0 (DE-625)153018:12905 |2 rvk | ||
| 100 | 1 | |a Papakostas, George I. |e Verfasser |0 (DE-588)139855335 |4 aut | |
| 245 | 1 | 0 | |a Pharmacotherapy for depression and treatment-resistant depression |c George I. Papakostas ; Maurizio Fava |
| 264 | 1 | |a Hackensack, NJ [u.a.] |b World Scientific |c 2010 | |
| 300 | |a xxv, 699 p. |b graph. Darst. | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b n |2 rdamedia | ||
| 338 | |b nc |2 rdacarrier | ||
| 500 | |a Includes bibliographical references and index | ||
| 500 | |a pt. 1. First-line pharmacotherapy strategies -- pt. 2. Next-step treatment strategies -- pt. 3. Maintaining treatment gains -- pt. 4. Future directions in treatment development | ||
| 650 | 4 | |a Depression, Mental / Chemotherapy | |
| 650 | 4 | |a Antidepressants | |
| 650 | 0 | 7 | |a Therapie |0 (DE-588)4059798-2 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Antidepressivum |0 (DE-588)4002263-8 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Chronische Depression |0 (DE-588)4198328-2 |2 gnd |9 rswk-swf |
| 689 | 0 | 0 | |a Antidepressivum |0 (DE-588)4002263-8 |D s |
| 689 | 0 | |5 DE-604 | |
| 689 | 1 | 0 | |a Chronische Depression |0 (DE-588)4198328-2 |D s |
| 689 | 1 | 1 | |a Therapie |0 (DE-588)4059798-2 |D s |
| 689 | 1 | |5 DE-604 | |
| 700 | 1 | |a Fava, Maurizio |e Verfasser |4 aut | |
| 856 | 4 | 2 | |m Digitalisierung UB Regensburg |q application/pdf |u http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=025111336&sequence=000003&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |3 Klappentext |
| 856 | 4 | 2 | |m Digitalisierung UB Regensburg |q application/pdf |u http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=025111336&sequence=000004&line_number=0002&func_code=DB_RECORDS&service_type=MEDIA |3 Inhaltsverzeichnis |
| 999 | |a oai:aleph.bib-bvb.de:BVB01-025111336 | ||
Datensatz im Suchindex
| _version_ | 1804149254240862208 |
|---|---|
| adam_text | Contents
About the Authors
vii
Preface
ix
1.
Major Depressive Disorder and Treatment-Resistant
Depression
1
1.1
Major Depressive Disorder
............. 1
1.1.1
Definition
................... 1
1.1.2
Prevalence and disease burden
....... 2
1.2
Treatment-Resistant Depression (TRD)
...... 4
1.2.1
Definition and staging
............ 4
1.2.2
Prevalence
.................. 10
1.2.3
Pseudo-resistance
............. 12
1.3
Demographic and Clinical Risk Factors for
Resistant Depression
................ 15
1.3.1
Studies focusing on SSRI therapy
..... 16
1.3.2
Studies focusing on therapy with older
antidepressants
................ 20
1.3.3
Studies focusing on therapy with newer
antidepressants
................ 22
Summary and Conclusion of Chapter
1......... 25
xiv
Pharmacotherapy
for Depression and Treatment-Resistant Depression
Part I: First-Line Pharmacotherapy Strategies
27
2.
Monoaminergic-Based Strategies:
Single-Acting Agents
29
2.1
Monoamine Precursors for Depression
...... 29
2.2
Selective Serotonin Reuptake
Inhibitors (SSRIs)
.................. 31
2.2.1
Neuropharmacology
............ 31
2.2.2
Efficacy (general)
............... 32
2.2.3
Efficacy in patients with medical
conditions
................... 37
2.2.3.1
Diabetes mellitus
......... 37
2.2.3.2
Coronary artery disease and
myocardial infarction
....... 38
2.2.3.3
Pulmonary and sleep
! disorders
.............. 39
2.2.3.4
Cerebrovascular illness
and stroke
............. 39
2.2.3.5
Movement disorders
....... 40
2.2.3.6
Epilepsy
;.............. 41
2.2.3.7,
Dementia
.............. 42
2.2.3.8
Renal insufficiency
........ 42
2.2.3.9
Hepatitis, cirrhosis, and
interferon
therapy
............... 43
2.2.3.10
Human immunodeficiency virus
43
2^2.3.11
Malignancy
............ 44
2.2.3.12
Transplant recipients
....... 45
2.2.4,
Side effect profile
............... 45
2.2.4.1
General
............... 45
2.2.4.2
Central nervous system
..... 46
2.2.4.3
Cardiovascular
.......... 51
2.2.4.4
Hematologie
............ 52
2.2.4.5
Endocrine
............. 54
2.2.4.6
Metabolic
.............. 57
2.2.4.7
Immunologie
........... 61
2.2.4.8
Dermatologie...........
61
2.2.4.9
Risk of malignancy
........ 62
Contents xv
2.2.4.10
Risk of teratogenicity
....... 62
2.2.4.11
Risk of transmission during
breastfeeding
........... 65
2.2.4.12
Discontinuation syndrome
.... 65
2.2.5
Dosing
..................... 66
2.2.5.1
Initial and optimal dose
..... 66
2.2.5.2
Serotonin transporter occupancy
as a function of dose
....... 67
2.2.5.3
Plasma levels and clinical
efficacy
............... 68
2.2.5
A Cytochrome enzyme genotype
and plasma levels
......... 69
2.2.5.5
P-glycoprotein interactions
... 70
2.2.6
Drug interactions
.............. 70
2.3
Serotonin Receptor Antagonists and Agonists
. . 70
2.3.1
Trazodone and nefazodone
......... 70
2.3.1.1
Neuropharmacology
....... 70
2.3.1.2
Efficacy
............... 71
2.3.1.3
Side effect profile
......... 73
2.3.1.4
Dosing
............... 76
2.3.2
Other 5HT-2 active agents
......... 76
2.3.2.1
Ritanserin
............. 76
2.3.2.2
Fenfluramine and
dexfenfluramine
.......... 76
2.3.2.3
Agomelatine
............ 77
2.3.3
5HT-1 active agents
............. 78
2.3.3.1
Agonists
.............. 78
2.3.3.2
Antagonists
............ 80
2.3.4
Agents acting on 5HT-3 and 5HT-4
.... 80
2.4
Serotonin Reuptake Enhancers
........... 81
2.5
a-2 Adrenergic Receptor Agonists
and Antagonists
................... 82
2.6
Norepinephrine Reuptake Inhibitors (NRIs)
... 82
2.6.1
Reboxetine
.................. 82
2.6.2
Atomoxetine
................. 85
2.6.3
Viloxazine
................... 85
xvi
Pharmacotherapy for Depression and Treatment-Resistant Depression
2.7
Selective
β
Adrenergic Receptor Agonists
.... 85
2.8
Dopamine-Selective Agents
............ 86
2.8.1
Receptor agonists
.............. 86
2.8.2
Reuptake inhibitors
............. 87
2.8.3
Receptor antagonists
............ 89
3.
Monoaminergic-Based Strategies: Dual-Acting Agents
91
3.1
Tricyclic Antidepressants (TCAs)
......... 91
3.1.1
Neuropharmacology
............ 91
3.1.2
Classification
................. 92
3.1.3
Efficacy
.................... 92
3.1.4
Side effect profile
............... 95
3.1.5
Dosing
..................... 100
3.2
Serotonin-Norepinephrine Reuptake Inhibitors
(SNRIs)
........................ 102
3.2.1
Venlafaxine
.................. 102
3.2.1.1
Neuropharmacology
....... 102
3.2.1.2
Efficacy
............... 102
3.2.1.3
Side effect profile
......... 106
3.2.1.4
Dosing
............... 109
3.2.2
Desvenlafaxine
................ 110
3.2.3
Duloxetine
..................
Ill
3.2.3.1
Efficacy
...............
Ill
3.2.3.2
Side effect profile
......... 113
3.2.3.3
Dosing
............... 114
3.2.4
Milnacipran
.................. 115
3.3
5HT-2 and a-2 Adrenergic Receptor
Antagonists
...................... 116
3.3.1
Mirtazapine.
................. 116
3.3.1.1
Neuropharmacology
....... 116
3.3.1.2
Efficacy
............... 117
3.3.1.3
Side effect profile
......... 119
3.3.1.4
Dosing
............... 121
3.3.2
Mianserin
................... 121
Contents xvii
3.4 Norepinephrine-Dopamine Reuptake
Inhibitors....................... 122
3.4.1 Bupropion .................. 122
3.4.1.1 Neuropharmacology....... 122
3.4.1.2
Efficacy
............... 123
3.4.1.3
Side effect profile.........
127
3.4.1.4
Dosing
............... 131
3.4.2
Nomifensine
................. 132
4.
Monoaminergic-Based Strategies:
Triple-Acting Agents
133
4.1
Monoamine
Oxidase
Inhibitors (MAOIs)
..... 133
4.1.1
Neuropharmacology
............ 133
4.1.2
Efficacy
.................... 134
4.1.3
Side effect profile
............... 137
4.1.3.1
Dietary restrictions and drug
interactions
............ 141
4.1.4
Dosing
..................... 141
4.2
Serotonin-Norepinephrine-Dopamine
Reuptake Inhibitors
................. 142
4.3
Catechol-O-Methyltransferase
(COMT) Inhibitors
.................. 143
5.
Polypharmacy from the Onset of Treatment
144
5.1
Adjunctive Treatment with Monoaminergic
Agents
......................... 144
5.1.1
Tryptophan
.................. 144
5.1.2
Pindolol
.................... 145
5.1.3
Typical antipsychotic agents
........ 148
5.1.4
5HT2 and a-2 adrenergic receptor
antagonists
.................. 149
5.1.5
Other antidepressants
............ 152
5.1.6
Atypical antipsychotic agents
....... 154
5.1.7
Dopaminergic agents
............ 156
5.1.8
Other monoaminergic agents
........ 156
xviii
Pharmacotherapy for Depression and Treatment-Resistant Depression
5.2
Adjunctive Treatment with
Neuroendocrine
Agents
. . . ... . . ................. 157
5.2.1
Thyroid hormones
.............. 157
5.2.2
Estrogen
...... . . ............ 159
5.2.3
Other
neuroendocrine
agents
........ 159
5.3
Other Agents
. ...... . ............. 161
5.3.1
Lithium
.................... 161
5.3.2
GABA-ergic agents
. ............ 162
5.3.3
Folates and s-adenosylmethionine
(SAMe)
. . . .
z.
. . . . . .■. :.-...... 165
5.3.4
Anticonvulsants
............... 167
5.3.5
Miscellaneous other agents
......... 168
Summary and Conclusion of Part I
.............. 174
Part II: Next-Step Treatment Strategies
. 177
6.
Polypharmacy Strategies for Treatment-Resistant
Depression
. 179
6.1
Adjunctive Treatment with Monoaminergic
Agents
.................. . ...■...■..... 179
6.1.1
Pindolol
........... .;. .,. . .... 179
6.1.2
5HT2 and a-2 adrenergic-receptor
antagonists
. . .... . . . . . ....... 181
6.1.3
Tricyclic antidepressants
........... 184
6.1.4
Selective 5HT1A agonists
.......... 184
6.1.5
Other antidepressants
............ 185
6.1.6
Atypical antipsychotic agents
....... 188
6.1.7
Dopaminergic agents
. . . ........ . 193
6.1.8
Other monoaminergic agents
........ 194
6.2
Adjunctive Treatment with
Neuroendocrine
Agents
............- . ............ 195
6.2.1
Thyroid hormones
.............. . 195
6.2.2
Androgens
.... . ............. 198
6.2.3
Estrogens
................... 199
Contents xix
6.2.4
Steroids and steroid synthesis
inhibitors
................... 199
6.2.5
Melatonin
................... 200
6.3
Other Agents
..................... 200
6.3.1
Lithium
.................... 200
6.3.2
ω
-З
fatty acids
................ 205
6.3.3
Modafinil
................... 206
6.3.4
Glutamatergic agents
............ 208
6.3.5
Anticonvulsants
............... 209
6.3.6
Inositol
.................... 211
6.3.7
Folates, s-adenosyl methionine
(SAMe)
and B-vitamins
................ 211
6.3.8
Cholinergic agents
.............. 213
6.3.9
Miscellaneous other agents
......... 214
7.
Monotherapy Strategies for Resistant Depression
215
7.1
Increasing the Dose of Antidepressants
...... 215
7.2
Switching Antidepressants Due to Lack
of Efficacy
....................... 219
7.2.1
Switching from a TCA to an SSRI
or MAOI and vice versa
........... 219
7.2.2
Switching to a TCA or an MAOI
following the failure of multiple
antidepressants
................ 222
7.2.3
Switching from one SSRI to another,
or to a non-SSRI antidepressant
...... 223
7.2.4
Other switch strategies
........... 227
8.
Non-pharmacologic Approaches for Resistant
Depression
229
8.1
Device-Based Therapies
............... 229
8.1.1
Electroconvulsive therapy
......... 229
8.1.2
Vagus nerve stimulation
.......... 231
8.1.3
Transcranial magnetic stimulation
..... 233
8.1.4
Deep brain stimulation
........... 235
xx
Pharmacotherapy
for Depression and Treatment-Resistant Depression
8.1.5
Transcranial direct current stimulation
(tDCS)
. .................... 235
8.1.6
Bright light therapy
............. 235
8.1.7
Acupuncture
................. 236
8.2
Psychotherapy
.................... 236
8.3
Exercise
........................ 239
8.4
Yoga and Meditation
................ 240
Summary and Conclusion of Part II
............... 241
Part III: Maintaining Treatment Gains
245
9.
Pharmacotherapy of Relapse/Recurrence Prevention
and Treatment
247
9.1
Antidepressant Continuation and Maintenance
Therapy Studies
. . ................. 247
9.1.1
Tricyclic antidepressants (TCAs)
...... 247
9.1.2
Monoamine
oxidase
inhibitors
(MAOIs).
. : . : ... .1 ......... 247
9.1.3
Selective serotonin reuptake
inhibitors (SSRIs)
............... 251
9.1.4
Newer antidepressants
........... 251
9.1.5
Summary of continuation and
maintenance trials
.............. 251
9.2
Special Topics in the Pharmacotherapy
of Relapse Prevention
. . . ...;......... 258
9.2.1
Long-term efficacy differences among
antidepressants
................ 258
9.2.2
Optimal duration of long-term
therapy
.................... 260
9.2.3
Long-term dosing and risk of
relapse
..................... 262
9.2.4
Continuing adjunctive agents during
long-term therapy
.............. 263
9.2.5
Instituting antidepressants among
non-medicated remitters
.......... 266
Contents xxi
9.2.6
Timing of symptom improvement and risk
of relapse
................... 267
9.2.7
Treatment-resistance and risk of relapse
. 268
9.3
Treatment of Depressive Relapse/Recurrence
. . 270
10.
Pharmacologie
Strategies to Enhance Antidepressant
Tolerability
272
10.1
Adjunctive Therapy
................. 272
10.1.1
Sexual dysfunction
............. 272
10.1.2
Fatigue and hypersomnia
.......... 275
10.1.3
Insomnia, anxiety, and activation
.... 277
10.1.4
Akathisia and bruxism
........... 280
10.1.5
Gastrointestinal symptoms
......... 280
10.1.6
Weight gain
.................. 281
10.1.7
Anticholinergic and other side effects
. . . 282
10.1.8
Cognitive side effects
............ 283
10.2
Switching Antidepressants Due
to Intolerance
..................... 283
Summary and Conclusion of Part III
............. 285
Part IV: Future Directions in Treatment Development
289
11.
Agents Operating on Non-monoaminergic
Neurotransmitter
Systems
291
11.1
GABA-ergic Treatments
............... 291
11.1.1
Benzodiazepines
............... 291
11.1.1.1
Clinical evidence
......... 291
11.1.1.2
Treatment limitations
....... 300
11.1.1.3
Neuropharmacology of
GAB
A
-А
receptors
........ 301
11.1.1.4
Conclusion
............. 302
11.1.2
Barbiturates
.................. 303
11.1.3
Other GABA-ergic agents
.......... 303
xxii
Pharmacotherapy
for Depression and Treatment-Resistant Depression
11.2
Glycine
and Glutamate-Based Treatments
.... 306
11.2.1
Neuropharmacology
............ 306
11.2.2
NMDA-active agents
............ 307
11.2.3
Other glutamatergic agents
......... 309
11.2.4
Glycinergic agents
.............. 311
11.3
Agents with Combined GABA-ergic and
Glutamatergic Activity
............... 311
11.3.1
Anticonvulsants
............... 311
11.4
Other Anticonvulsants
............... 314
11.5
Neurokinin-Receptor Antagonists
......... 316
11.5.1
Neuropharmacology
............ 316
11.5.2
Clinical evidence
............... 316
11.6
Nicotinic Receptor-Based Treatments
....... 319
11.6.1
Neuropharmacology
............ 319
11.6.2
Nicotinic-receptor agonists
......... 319
11.6.3
Cholinesterase inhibitors
.......... 321
11.6.4
Nicotinic-receptor antagonists
....... 322
11.7
Cannabinoids and Endocannabinoids
....... 322
11.8
Opioidergic Therapies
................ 324
11.8.1
Opioid-receptor antagonists
........ 324
11.8.2
Opioid-receptor agonists
.......... 324
11.8.3
Mixed agonists/antagonists
........ 325
11.9
Other
Neurotransmitter
Systems
.......... 326
12.
Neuroendocrine-Based Agents
328
12.1
Hypothalamic-Pituitary-Gonadal
Axis(HPG)
...................... 328
12.1.1
Estrogen
.................... 328
12.1.2
Progesterone
................. 332
12.1.3
Androgens
.................. 333
12.1.4
Dehydroepiandrosterone (DHEA)
..... 337
12.1.5
Other gonadotropic agents
......... 338
12.2
Hypothalamic-Pituitary-Adrenal
Axis
(ΗΡΑ)
...................... 338
12.2.1
Corticosteroids
................ 338
12.2.2
Steroid synthesis inhibitors
......... 339
Contents xxiii
12.2.3
Steroid-
and CRF-receptor
antagonists
.................. 340
12.3
Hypothalamic-Pituitary-Thyroid
Axis (HPT)
...................... 342
12.4
Melatonin and Melatonergic Agents
......... 343
12.5
Other Hormones
................... 345
13.
Metabolic-Based and Other Agents
348
13.1
Metabolic-Based Agents
............... 348
13.1.1
Elements of the one carbon cycle
.... 348
13.1.1.1
S-adenosylmethionine
(SAMe)
............... 348
13.1.1.2
Folates and other B-vitamins
. . 353
13.1.2
Agents acting on
neuronal
second
messenger systems
............. 353
13.1.2.1
Anatomy of the second
messenger system
........ 353
13.1.2.2
Phosphodiesterase
inhibitors
.............. 354
13.1.2.3
Inqsitol
............... 355
13.1.2.4
Other agents
............ 355
13.1.3
Essential fatty acids
............. 356
13.1.3.1
Overview
.............. 356
13.1.3.2
Clinical studies
.......... 357
13.1.4
Carnitine
................... 360
13.1.5
Minerals, trace elements, and vitamins
(non-B vitamins)
............... 362
13.2
Agents with Unknown Mechanism
of Action
....................... 363
13.2.1
Herbal remedies
............... 363
13.2.1.1
Hypericum perforatum
....... 363
13.2.1.2
Ginseng
.............. 368
13.2.1.3
Kavakava
............. 368
13.2.1.4
Valerian root and
Ginkgo bilboa . 369
13.2.2
Modafinil
................... 369
13.2.3
Pivagabine
.................. 370
xxiv
Pharmacotherapy for Depression and Treatment-Resistant Depression
14.
Biological Predictors, Moderators, and Mediators
of Efficacy
.... 371
14.1
Definition and Significance of Mediators
of Outcome
...·. . .·. ............... 371
14.2
Genetic Markers
................... 373
14.2.1
Studies involving SSRI therapy
...... 376
14.2.1.1
Genes coding for TPH
and5HTT
............. 376
14.2.1.2
Genes coding for
SHT-receptors
........... 377
14.2.1.3
Genes coding for NET
or NE-receptors
.......... 377
14.2.1.4
Genes coding for MAO and
COMT
............... 378
14.2.1.5
Genes coding for other
proteins
............... 378
14.2.2
Studies involving therapy with other
antidepressants
. . .............. 380
14.2.3
Studies comparing antidepressants
.... 382
14.3
Neurophysiology
.................. 385
14.3.1
Brain functioning and metabolism
..... 385
14.3.1.1
Positron emission
tomography
............ 385
14.3.1.2
Functional magnetic resonance
imaging
.............. 386
14.3.1.3
Magnetic resonance
spectroscopy
............ 387
14.3.2
Electroencephalography
.......... 388
14.3.2.1
Traditional
electroencephalography
..... 388
14.3.2.2
Quantitative
electroencephalography
..... 389
14.3.2.3
Loudness Dependence of Auditory
Evoked Potentials (LDAEP)
... 391
Contents xxv
14.3.3
Brain functional asymmetry (dichotic
listening)
................... 392
14.4
Molecular Biology
.................. 393
14.4.1
Receptor and transporter kinetics
..... 393
14.4.2
Intracellular signal transduction
...... 394
14.4.3
Inflammatory markers
........... 396
Summary and Conclusion of Part IV
............. 399
Appendix A
........................... 401
Appendix
В
........................... 403
AppendixC
........................... 405
Appendix
D
........................... 407
Bibliography
409
Chapter
1 .......................... 409
Chapter
2.......................... 422
Chapter
3.......................... 493
Chapter
4.......................... 535
Chapter
5........ .................. 544
Chapter
6.......................... 560
Chapter
7.......................... 587
Chapter
8.......................... 594
Chapter
9.......................... 601
Chapter
10.......................... 610
Chapter
11.......................... 625
Chapter
12.......................... 650
Chapter
13.......................... 662
Chapter
14........................... 676
Index
695
is
upique and ground-breaking:work, autnored
■
^ѓ^
W.B
bU
I .^V^W^V·
ΐ
■
^р^^%Лв ^Ц
■
^Ј ^- ^^ %^9
?&
v MUUI^yy
^«I^Ã^M
involvingatheşusefofşant depressar.
iocusing-onła^eparatei^hemeltnaiwillifacilitate
|
| any_adam_object | 1 |
| author | Papakostas, George I. Fava, Maurizio |
| author_GND | (DE-588)139855335 |
| author_facet | Papakostas, George I. Fava, Maurizio |
| author_role | aut aut |
| author_sort | Papakostas, George I. |
| author_variant | g i p gi gip m f mf |
| building | Verbundindex |
| bvnumber | BV040255451 |
| classification_rvk | XI 5800 |
| ctrlnum | (OCoLC)802350605 (DE-599)BVBBV040255451 |
| discipline | Medizin |
| format | Book |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>02247nam a2200469zc 4500</leader><controlfield tag="001">BV040255451</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">20120725 </controlfield><controlfield tag="007">t</controlfield><controlfield tag="008">120616s2010 d||| |||| 00||| eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9789814287586</subfield><subfield code="9">978-981-4287-58-6</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">981428758X</subfield><subfield code="9">981-4287-58-X</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9789814287593</subfield><subfield code="c">ebook</subfield><subfield code="9">978-981-4287-59-3</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)802350605</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV040255451</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">aacr</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-355</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">XI 5800</subfield><subfield code="0">(DE-625)153018:12905</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Papakostas, George I.</subfield><subfield code="e">Verfasser</subfield><subfield code="0">(DE-588)139855335</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Pharmacotherapy for depression and treatment-resistant depression</subfield><subfield code="c">George I. Papakostas ; Maurizio Fava</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Hackensack, NJ [u.a.]</subfield><subfield code="b">World Scientific</subfield><subfield code="c">2010</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">xxv, 699 p.</subfield><subfield code="b">graph. Darst.</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">Includes bibliographical references and index</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">pt. 1. First-line pharmacotherapy strategies -- pt. 2. Next-step treatment strategies -- pt. 3. Maintaining treatment gains -- pt. 4. Future directions in treatment development</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Depression, Mental / Chemotherapy</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Antidepressants</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Therapie</subfield><subfield code="0">(DE-588)4059798-2</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Antidepressivum</subfield><subfield code="0">(DE-588)4002263-8</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Chronische Depression</subfield><subfield code="0">(DE-588)4198328-2</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">Antidepressivum</subfield><subfield code="0">(DE-588)4002263-8</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="689" ind1="1" ind2="0"><subfield code="a">Chronische Depression</subfield><subfield code="0">(DE-588)4198328-2</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="1" ind2="1"><subfield code="a">Therapie</subfield><subfield code="0">(DE-588)4059798-2</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="1" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Fava, Maurizio</subfield><subfield code="e">Verfasser</subfield><subfield code="4">aut</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="m">Digitalisierung UB Regensburg</subfield><subfield code="q">application/pdf</subfield><subfield code="u">http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=025111336&sequence=000003&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA</subfield><subfield code="3">Klappentext</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="m">Digitalisierung UB Regensburg</subfield><subfield code="q">application/pdf</subfield><subfield code="u">http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=025111336&sequence=000004&line_number=0002&func_code=DB_RECORDS&service_type=MEDIA</subfield><subfield code="3">Inhaltsverzeichnis</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-025111336</subfield></datafield></record></collection> |
| id | DE-604.BV040255451 |
| illustrated | Illustrated |
| indexdate | 2024-07-10T00:20:06Z |
| institution | BVB |
| isbn | 9789814287586 981428758X 9789814287593 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-025111336 |
| oclc_num | 802350605 |
| open_access_boolean | |
| owner | DE-355 DE-BY-UBR |
| owner_facet | DE-355 DE-BY-UBR |
| physical | xxv, 699 p. graph. Darst. |
| publishDate | 2010 |
| publishDateSearch | 2010 |
| publishDateSort | 2010 |
| publisher | World Scientific |
| record_format | marc |
| spelling | Papakostas, George I. Verfasser (DE-588)139855335 aut Pharmacotherapy for depression and treatment-resistant depression George I. Papakostas ; Maurizio Fava Hackensack, NJ [u.a.] World Scientific 2010 xxv, 699 p. graph. Darst. txt rdacontent n rdamedia nc rdacarrier Includes bibliographical references and index pt. 1. First-line pharmacotherapy strategies -- pt. 2. Next-step treatment strategies -- pt. 3. Maintaining treatment gains -- pt. 4. Future directions in treatment development Depression, Mental / Chemotherapy Antidepressants Therapie (DE-588)4059798-2 gnd rswk-swf Antidepressivum (DE-588)4002263-8 gnd rswk-swf Chronische Depression (DE-588)4198328-2 gnd rswk-swf Antidepressivum (DE-588)4002263-8 s DE-604 Chronische Depression (DE-588)4198328-2 s Therapie (DE-588)4059798-2 s Fava, Maurizio Verfasser aut Digitalisierung UB Regensburg application/pdf http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=025111336&sequence=000003&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA Klappentext Digitalisierung UB Regensburg application/pdf http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=025111336&sequence=000004&line_number=0002&func_code=DB_RECORDS&service_type=MEDIA Inhaltsverzeichnis |
| spellingShingle | Papakostas, George I. Fava, Maurizio Pharmacotherapy for depression and treatment-resistant depression Depression, Mental / Chemotherapy Antidepressants Therapie (DE-588)4059798-2 gnd Antidepressivum (DE-588)4002263-8 gnd Chronische Depression (DE-588)4198328-2 gnd |
| subject_GND | (DE-588)4059798-2 (DE-588)4002263-8 (DE-588)4198328-2 |
| title | Pharmacotherapy for depression and treatment-resistant depression |
| title_auth | Pharmacotherapy for depression and treatment-resistant depression |
| title_exact_search | Pharmacotherapy for depression and treatment-resistant depression |
| title_full | Pharmacotherapy for depression and treatment-resistant depression George I. Papakostas ; Maurizio Fava |
| title_fullStr | Pharmacotherapy for depression and treatment-resistant depression George I. Papakostas ; Maurizio Fava |
| title_full_unstemmed | Pharmacotherapy for depression and treatment-resistant depression George I. Papakostas ; Maurizio Fava |
| title_short | Pharmacotherapy for depression and treatment-resistant depression |
| title_sort | pharmacotherapy for depression and treatment resistant depression |
| topic | Depression, Mental / Chemotherapy Antidepressants Therapie (DE-588)4059798-2 gnd Antidepressivum (DE-588)4002263-8 gnd Chronische Depression (DE-588)4198328-2 gnd |
| topic_facet | Depression, Mental / Chemotherapy Antidepressants Therapie Antidepressivum Chronische Depression |
| url | http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=025111336&sequence=000003&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=025111336&sequence=000004&line_number=0002&func_code=DB_RECORDS&service_type=MEDIA |
| work_keys_str_mv | AT papakostasgeorgei pharmacotherapyfordepressionandtreatmentresistantdepression AT favamaurizio pharmacotherapyfordepressionandtreatmentresistantdepression |